My watch list
my.bionity.com  
Login  

Clinical Trial Manager (gn)

Advertisement No. CK/1010760
More about MorphoSys
  • Job Offers

    Medical Director / Medical Scientist (gn) in Clinical Development

    We would like to fill the following vacancy as soon as possible: Provide medical expertise to clinical programs for tafasitamab – in the area of oncology. Focus on design, timely preparation and execution of the clinical trial(s) Prepare or oversee preparation of clinical trial protoco ... more

    Scientist Clinical Biomarkers (gn)

    We would like to fill the following vacancy as soon as possible: Develop and implement clinical biomarker strategies in collaboration with clinical department Identify Contract Research Organizations (CROs) for outsourced biomarker testing in the context of clinical trials Manage C ... more

    Team Leader Clinical Biomarkers (gn)

    We would like to fill the following vacancy as soon as possible: Lead a team of five scientists involved in clinical biomarker research Drive development and implementation of clinical biomarker strategies in collaboration with clinical department Identify Contract Research Organizations ( ... more

  • News

    MorphoSys and Vivoryon Therapeutics Enter Agreement in Immuno-Oncology

    MorphoSys AG and Vivoryon Therapeutics AG announced that they have entered into an agreement under the terms of which MorphoSys has obtained an exclusive option to license Vivoryon's small molecule QPCTL inhibitors in the field of oncology. The option covers worldwide development and commer ... more

    MorphoSys Appoints Jean-Paul Kress as New CEO

    MorphoSys AG announced that its Supervisory Board has appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer (CEO). The appointment will take effect on September 1, 2019. Dr. Kress brings over 20 years of experience in the pharmaceutical and biotechnology industry, with a stron ... more

    MorphoSys received a milestone payment from Janssen

    MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has further expanded the clinical development of guselkumab (Tremfya(R)) into familial adenomatous polyposis (FAP), a disease of the gastrointestinal tract. Janssen has initiated a phase 1b proof-of-concept clinic ... more

  • Companies

    MorphoSys AG

    MorphoSys AG, located in Martinsried/Munich, is one of the worlds leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of therapeutic antibodies which can be used not only for research and diagnostics b ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE